Acumen Pharmaceuticals (ABOS)
US Market

Acumen Pharmaceuticals (ABOS) Income Statement


Acumen Pharmaceuticals Income Statement

Last quarter (Q1 2023), Acumen Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Acumen Pharmaceuticals's net income was $-11.31M. See Acumen Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ -1.00K$ 43.00K$ 0.00$ 0.00$ 1.70M
Cost of Revenue
Gross Profit
$ -1.00K$ 43.00K---
Operating Expense
$ 20.67M$ -45.24M$ 19.58M$ 7.91M$ 9.50M
Operating Income
$ -49.17M$ -45.24M$ -19.58M$ -7.91M$ -7.80M
Net Non Operating Interest Income Expense
$ 4.15M$ 2.39M$ 84.00K$ 1.00K$ 45.00K
Other Income Expense
$ 12.00K$ 11.00K$ -81.11M$ 586.00K$ -147.00K
Pretax Income
$ -45.03M$ -42.86M$ -100.61M$ -7.33M$ -7.91M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -45.03M$ -42.86M$ -100.61M$ -7.33M$ -7.69M
Basic EPS
$ -1.34$ -1.06$ -5.02$ -0.28$ -0.27
Diluted EPS
$ -1.11$ -1.06$ -5.02$ -0.28$ -0.27
Basic Average Shares
$ 162.63M$ 40.60M$ 20.06M$ 28.65M$ 28.65M
Diluted Average Shares
$ 162.63M$ 40.60M$ 20.06M$ 28.65M$ 28.65M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 20.67M$ -45.24M$ 19.58M$ 7.91M$ 9.50M
Net Income From Continuing And Discontinued Operation
$ -45.03M$ -42.86M$ -100.61M$ -7.33M$ -7.91M
Normalized Income
$ -20.86M-$ -19.45M$ -7.91M$ -7.76M
Interest Expense
$ -49.18M$ -45.25M$ -19.58M$ -7.91M$ -7.80M
$ -49.42M$ -44.59M$ -19.58M$ -7.91M$ -7.80M
Currency in USD

Acumen Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis